Clinical Trials Logo

Central Nervous System Tumors clinical trials

View clinical trials related to Central Nervous System Tumors.

Filter by:

NCT ID: NCT01067196 Completed - Clinical trials for Central Nervous System Tumors

Outcomes Study of Late Effects After Proton RT for Pediatric Tumors of the Brain, Head, and Neck

CN01
Start date: February 2010
Phase:
Study type: Observational

The purpose of this study is to collect information from medical records to see what effects proton beam radiation has on cancer and analyze possible side effects.

NCT ID: NCT01052363 Withdrawn - Clinical trials for Central Nervous System Tumors

OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas

Start date: January 2010
Phase: Phase 1
Study type: Interventional

Pilot Trial of CA4P with Avastin in Recurrent Gliomas

NCT ID: NCT00945828 Completed - Lymphoma Clinical Trials

Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors

Start date: January 2003
Phase: N/A
Study type: Interventional

Neurodevelopmental outcomes in children treated for cancer involving the central nervous system (CNS) provide educators with new challenges with regards to classification, monitoring, and intervention in the regular or special education classroom setting. Recommendations resulting from serial neurodevelopmental evaluations for these children often do not overlap with traditional special education recommendations commonly included in Individual Education Plans (IEPs) for children with congenital or genetic learning problems. The investigators currently do not know whether or not school-based treatment for learning problems, based on the child's IEP, incorporates recommendations made based on a neurodevelopmental evaluation appropriately. In addition, it is not clear whether or not the recommendations that are included in a child's IEP have any beneficial outcome on the child's learning and academic achievement over time. The purpose of this project is to examine the relationship between neurodevelopmental outcomes, recommendations for intervention, special education services and accommodations included in a child's school IEP, and outcome for the child following implementation of the IEP. The study has two major specific aims: 1. To quantify the clinical and educational contributions of recommendations resulting from neurodevelopmental evaluations and the subsequent development of IEPs. Hypothesis 1.1: Higher concordance between recommendations made based on neurodevelopmental evaluations and criteria written into children's IEPs will be associated with more positive academic outcomes (i.e. maintenance or improvement in academic skills). Hypothesis 1.2: Children who have higher concordance between criteria written into their IEPs and academic services actually received will show more positive academic outcomes than children whose IEP criteria and academic services are less concordant. 2. To evaluate an intervention that will improve academic outcomes for children treated for cancer. Hypothesis 2.1: Children whose IEPs are monitored more frequently will show more positive academic outcomes than their peers whose IEPs are monitored less frequently.

NCT ID: NCT00899834 Completed - Brain Tumors Clinical Trials

DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma

Start date: June 2006
Phase: N/A
Study type: Observational

This multi-institutional study will prospectively collect tumor and constitutional tissue samples from patients with diffuse brainstem glioma and other types of brainstem gliomas either during therapy or at autopsy to perform an extensive analysis of genetic and molecular abnormalities in these tumors.

NCT ID: NCT00876993 Completed - Clinical trials for Central Nervous System Tumors

Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors

Start date: September 2008
Phase: Phase 1
Study type: Interventional

Bevacizumab, irinotecan, and temozolomide are three agents shown to have promising activity in a variety of central nervous system tumors. No prospective studies have been published or are currently in progress within the major consortiums with this combination of drugs. Brain tumors are the second most common cause of cancer in pediatrics and the leading cause of cancer death in children. For children with High Grade Gliomas or with relapsed/refractory brain tumors, new agents in new combinations are needed. Historical data shows that newly diagnosed high grade gliomas 5 year progression free survival is 28-42%. Recurrent malignant gliomas median survival is 3-9 months. Recurrent medulloblastoma's 2 years survival is 9%. This study is a phase I study designed to provide an objective observation of toxicity and establish a maximum tolerated dose of this combination. In addition, this study will observe the response of children with relapsed or refractory central nervous system tumors.

NCT ID: NCT00607984 Recruiting - Tumors Clinical Trials

Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors

Start date: June 2006
Phase: N/A
Study type: Interventional

The prognosis of children and adolescents with high risk tumors of the central nervous system and other miscellaneous solid tumors is poor despite modern treatment protocols. Frequently, physicians suggest additional therapy with high dose chemotherapy after a good initial response to standard doses of treatment has been obtained, so as to reduce the chance that the tumor will recur. We propose a regimen of high dose thiotepa and melphalan followed by rescue of the patient's previously stored hematopoietic (blood manufacturing) system with blood stem cells. The aim of this study is to prove that this therapy is tolerable in children and adolescents, that it results in tolerable levels of toxicity, and that it improves the survival of this group of children as compared to standard therapy given in the past

NCT ID: NCT00477503 Terminated - Brain Tumors Clinical Trials

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

Start date: May 2007
Phase: Phase 1
Study type: Interventional

- Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative radiopharmaceutical for CSF imaging. - Secondary Objective will be to evaluate the biodistribution, pharmacokinetics and radiation dosimetry of In 111 DTPA and gallium-67 after intrathecal injection during remission of leptomeningeal metastasis (LM) and during LM occurrence, remission and recurrence.

NCT ID: NCT00407433 Completed - Neuroblastoma Clinical Trials

Clinical Studies of Gemcitabine-Oxaliplatin

Start date: n/a
Phase: Phase 2
Study type: Interventional

These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.

NCT ID: NCT00400816 Completed - Brain Tumor Clinical Trials

Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma

Start date: August 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with newly diagnosed anaplastic oligodendroglioma or mixed oligoastrocytoma.

NCT ID: NCT00187226 Completed - Brain Tumors Clinical Trials

A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects

Start date: June 1997
Phase: Phase 2
Study type: Interventional

The purpose of the study was to determine if treating a limited volume of normal tissue surrounding the tumor or tumor bed using conformal radiation therapy would achieve similar rates of disease control compared to standard radiation therapy. The study was also conducted to examine the effect of irradiation on neurological, endocrine and cognitive function.